1Kelley JR, Duggn JM. Gastric cancer epidemiology and risk fac- tors [ J] . Clin Epidemio1,2003,56 ( 1 ) : 1 - 9.
2李恩孝.恶性肿瘤分子靶向治疗[M].第2版.北京:人民卫生出版社,2011:358-78.
3Cutsem E, Kang Y, Chung H, et al. Efficacy results from the TOGAtrial: a phase I study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor re- ceptor- 2 ( HER2 ) positive advanced gastric cancer (GC) [ C ]. ASCO Meeting Abstracts, 2009:46-53.
4Doi T, Koizumi W, Siena S, et al. Efficacy, tolerability and pharma- cokinetics of gefitinib ( ZD1839 ) in pretreated patients with meta- static gastric cancer[ J ]. Proc Am Soc Clin Oncol,2005 (22) : 321 - 328.
5Adelstein DJ, Rybicki LA, Carroll MA,et al. Phase II trial of ge- fitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer [ J ]. Proc Am SocClin 0ncol,2005,23 (16) :4054a.
6Roth A, Moehler MH, Maaer M. Lapatinib in combination with ECF/X in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer ( GC ) : A phase ]I randomized placebo controlled trial (EORTC 40071 ) [ C ]. Clin Onco, 2010 ASCO Annual Meeting Proceedings, 2010 (28) :27- 34.
7Tebbutt NC, Sourjina T, Strickland AH, et al. ATTAX2: Do- cetaxel plus cetuximab as second-line treatment for docetaxel-re- fractory oesophago-gastric cancer-Final results of a multicenter phase 1I trial by the AGITG [ C ]. ASCO Meeting Abstracts, 2008 : 342- 349.
8Woell E, Greil R. Eisterer W, et al. Oxaliplatin, Irinotecan and Cetuximab in advanced gastric cancer: First results of a multi- center phase I1 trial (AGMT Gastric-2) [C ]. ASCO Meeting Ab- stracts, 2008:213-221.
9Moehler M, Mueller T, Trarbach T, et al. Cetuximab with irinote- can, folinic acid and 5-fluorouracil as first-line treatment in ad- vanced gastroesophageal cancer: a prospective multi-center bin- marker- oriented phase l/study [ J ]. Ann Oncol, 2011, 22 ( 6 ) : 1358-1366.
10Lordick F, Kang YK, Chung HC, et al. Capecitabine and cispla- tin with or without cetuximab for patients with previously untreated advanced gastric cancer ( EXPAND ) : a randonaised, open-labelphase 3 trial[J]. Lancet Oneol, 2013,14(6) :490-499.
3Liu X,Erikson RL.Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of plk1 by siRNA.Proc Natl Acad Sci,2002,99:8672-8676.
4Smith MR,Wilson ML,Hamanaka R,et al.Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase.Biochem Biophys Res Commun,1997,234:397-405.
5Takahashi T,Sano B,Nagata T,et al.Polo-like kinase 1 (plk1) is overexpressed in primary colorectal cancers.Cancer Sci,2003,94:148-152.
6Weichert W,Denkert C,Schmidt M,et al.Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma.Br J Cancer,2004,90:815-821.
7Tokumitsu Y,Mori M,Tanaka S,et al.Prognostic significance of polo-like kinase expression in esophageal carcinoma.Int J Oncol,1999,15:687-692.
8Wolf G,Elez R,Doermer A,et al.Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer.Oncogene,1997,14:543-549.
9Knecht R,Elez R,Oechler M,et al.Prognostic significance of polo-like kinase(PLK) expression in squamous cell carcinomas of the head and neck.Cancer Res,1999,59:2794-2797.
10Kneisel L,Strebhardt K,Bernd A,et al.Expression of pololike kinase (plk1) in thin melanomas:a novel marker of metastatic disease.J Cutan Pathol,2002,29:354-358.
1Kemal Y, Yucel I, Ekiz K, et al. Elevated Serum Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios Could be Useful in Lung Cancer Diagnosis[J]. Asian Pae J Cancer Prey, 2014,15(6) :2651 -2654.
2Kaynar M, Yildirim ME, Badem H, et al. Bladder cancer invasion predictahility based on preoperative neutrophil- lymphocyte ratio [ J ]. Tumour Biol, 2014, [ Epub ahead of print].
3Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow [J] ? Lancet, 2001,357(9255) :539 -545.
4Wei K, Wang M, Zhang W, et al. Neutrophil - lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib [ J ]. Med Oncol, 2014,31 (6) :969.
5Sonpavde G, Pond GR, Armstrong A J, et al. Prognostic Impact of the Neutrophil - to - Lymphocyte Ratio in Men With Metastatic Castration - Resistant Prostate Cancer [J]. CAin Genitourin Cancer, 2014, pii: S1558 - 7673 (14) 00054 - 00058.
6Suzuki K, Kachala SS, Kadota K, et al. Prognostic immune markers in non -small cell lung cancer[J]. CAin Cancer Res, 2011,17(16) :5247 -5256.
7Ohashi R, Takabashi K, Miura K, et al. Prognostic factors in patients with inoperable non - small cell lung cancer - an analysis of long - term survival patients [ J]. Gan To Kagaku Ryoho, 2006,33 ( 11 ) : 1595 - 1602.
